SAN RAMON, CA--(Marketwire - June 18, 2012) - BioVentrix, the developer of minimally invasive therapies for the treatment of heart failure, announced the election of Mr. George J. Fazio and Mr. Steven J. Healy to its board of directors at the recent annual meeting held in New York City.
Mr. Fazio has held leadership positions in the medical device field for twenty-five years. He joined DC Devices, Inc. in 2010, a med-tech device company developing a novel interventional treatment for diastolic heart failure, as president and chief executive officer. Prior to DC Devices, he was at St. Jude Medical, Inc. from 1992-2009, where he held numerous positions with increasing responsibility. At St. Jude Medical, where Mr. Fazio began as a sales representative, he rose to leadership positions in the Global Cardiac Businesses as president of the U.S. Division, president of the Cardiovascular Division, president of the Cardiac Surgery Division, president of Europe, Middle East, Africa (EMEA), and general manager of its Canadian Operations. Prior to joining St. Jude Medical, Mr. Fazio held multiple positions in sales, sales management and marketing at Davis & Geck in its Surgical Business.
Mr. Healy is currently president of Zimmer Spine. Prior to joining Zimmer Spine, he served as chairman, chief executive officer, and a founding board member of Lumen Biomedical Inc., an interventional cardiology company. Before joining Lumen, he was chief executive officer of Disc Dynamics, Inc., an orthopedic medical technology company where he served from July 2002 to June 2009. Prior to this, he was president of the Cardiac Surgery Division at St. Jude Medical, where he held a variety of senior management positions prior to being promoted to president. Mr. Healy joined St. Jude Medical in 1983.
"We are pleased to have George and Steve join our board of directors, as they both bring a wealth of expertise and insight directly applicable to our business," said Michael Taglich, chairman of the board of directors for BioVentrix. "They have reviewed our promising clinical data and business plan, and they are confident that they will help to make this company the success it should be."
"We welcome our newly elected board members and we greatly value their collective knowledge and extensive experience in healthcare, particularly in interventional cardiology and cardiac surgery," said Kenneth Miller, president and chief executive officer of BioVentrix. "I am confident that the vast, collective experience of BioVentrix's board of directors will help to build upon our accomplishments and further enhance opportunities to drive value for our innovative, less invasive approach to treating heart failure."
BioVentrix is a privately held medical device company headquartered in San Ramon, Calif., U.S.A. Its mission is to improve and expand on the treatment of heart failure, primarily through the development of less invasive, catheter-based approaches. The company's proprietary system offers a less invasive, accelerated recovery treatment that improves cardiac function by restoring the geometry and resulting function of the left ventricle, thereby improving a patient's quality of life. The company's clinical investigators include some of the world's leading surgeons and cardiologists. The BioVentrix system is an investigational device pending CE Mark. For more information, please visit: http://bioventrix.com.